LORICRIN and melanoma: Immunohistochemistry was used to analyse AMBRA1 and TGF‐β2 in a cohort of 109 AJCC all‐stage melanomas, and TGF‐β2 and claudin‐1 in a cohort of 30 or 42 AJCC stage I melanomas, respectively, with known AMBRA1 and loricrin (AMLo) expression.